Full text is available at the source.
Resmetirom for Steatotic Liver Disease: Does Data Support Widespread Use?
Does Resmetirom Work Well Enough for Common Fatty Liver Disease to Be Used Widely?
AI simplified
Page updated
Abstract
Resmetirom has received accelerated FDA approval based on its safety and efficacy in achieving metabolic dysfunction-associated steatohepatitis (MASH) resolution and fibrosis regression.
- Resmetirom is a liver-directed thyroid hormone receptor beta agonist.
- It is associated with improvements in liver histology for patients with MASH and significant fibrosis.
- The MAESTRO trial provided evidence for its reasonable safety profile.
- Noninvasive tests may be useful for selecting and monitoring patients receiving resmetirom.
- The review discusses the real-world utility of resmetirom in treating liver disease.
AI simplified